199 related articles for article (PubMed ID: 32290440)
1. The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications.
Recagni M; Bidzinska J; Zaffaroni N; Folini M
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290440
[TBL] [Abstract][Full Text] [Related]
2. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.
Cimino-Reale G; Gandellini P; Santambrogio F; Recagni M; Zaffaroni N; Folini M
J Hematol Oncol; 2017 Jul; 10(1):140. PubMed ID: 28716051
[TBL] [Abstract][Full Text] [Related]
3. Alternative lengthening of telomeres (ALT) and chromatin: is there a connection?
Nittis T; Guittat L; Stewart SA
Biochimie; 2008 Jan; 90(1):5-12. PubMed ID: 17935854
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of telomerase induces alternative lengthening of telomeres during human esophageal carcinogenesis.
Queisser A; Heeg S; Thaler M; von Werder A; Opitz OG
Cancer Genet; 2013 Nov; 206(11):374-86. PubMed ID: 24331919
[TBL] [Abstract][Full Text] [Related]
5. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
De Vitis M; Berardinelli F; Sgura A
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
[TBL] [Abstract][Full Text] [Related]
6. Alternative Lengthening of Telomeres in the Budding Yeast
Cohn M; Andersson AK; Mateo RQ; Möller MC
G3 (Bethesda); 2019 Oct; 9(10):3345-3358. PubMed ID: 31427453
[TBL] [Abstract][Full Text] [Related]
7. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
8. Telomere maintenance in Wilms tumors: first evidence for the presence of alternative lengthening of telomeres mechanism.
Venturini L; Daidone MG; Motta R; Collini P; Spreafico F; Terenziani M; Piva L; Radice P; Perotti D; Zaffaroni N
Genes Chromosomes Cancer; 2011 Oct; 50(10):823-9. PubMed ID: 21769957
[TBL] [Abstract][Full Text] [Related]
9. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
Grobelny JV; Kulp-McEliece M; Broccoli D
Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells.
Perrem K; Colgin LM; Neumann AA; Yeager TR; Reddel RR
Mol Cell Biol; 2001 Jun; 21(12):3862-75. PubMed ID: 11359895
[TBL] [Abstract][Full Text] [Related]
11. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
12. Variations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancer.
Heeg S
Pharmgenomics Pers Med; 2015; 8():171-80. PubMed ID: 26675332
[TBL] [Abstract][Full Text] [Related]
13. Telomere maintenance by telomerase and by recombination can coexist in human cells.
Cerone MA; Londono-Vallejo JA; Bacchetti S
Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
George SL; Parmar V; Lorenzi F; Marshall LV; Jamin Y; Poon E; Angelini P; Chesler L
J Exp Clin Cancer Res; 2020 May; 39(1):78. PubMed ID: 32375866
[TBL] [Abstract][Full Text] [Related]
15. [ALT--alternative lengthening of telomere].
Wu XM; Tang WR; Luo Y
Yi Chuan; 2009 Dec; 31(12):1185-91. PubMed ID: 20042385
[TBL] [Abstract][Full Text] [Related]
16. Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids.
Perrem K; Bryan TM; Englezou A; Hackl T; Moy EL; Reddel RR
Oncogene; 1999 Jun; 18(22):3383-90. PubMed ID: 10362359
[TBL] [Abstract][Full Text] [Related]
17. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.
Ulaner GA; Hoffman AR; Otero J; Huang HY; Zhao Z; Mazumdar M; Gorlick R; Meyers P; Healey JH; Ladanyi M
Genes Chromosomes Cancer; 2004 Oct; 41(2):155-62. PubMed ID: 15287028
[TBL] [Abstract][Full Text] [Related]
18. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
Zhao S; Wang F; Liu L
Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
[TBL] [Abstract][Full Text] [Related]
19. Augmented telomerase activity, reduced telomere length and the presence of alternative lengthening of telomere in renal cell carcinoma: plausible predictive and diagnostic markers.
Pal D; Sharma U; Khajuria R; Singh SK; Kakkar N; Prasad R
Gene; 2015 May; 562(2):145-51. PubMed ID: 25769384
[TBL] [Abstract][Full Text] [Related]
20. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.
Fasching CL; Bower K; Reddel RR
Cancer Res; 2005 Apr; 65(7):2722-9. PubMed ID: 15805271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
